sirturo.com
Clinical Trials |SIRTURO® (bedaquiline) | Official Site
http://www.sirturo.com/sirturo-clinical-trials
FOR HEALTHCARE PROFESSIONALS IN THE US AND PUERTO RICO ONLY. A placebo-controlled, double-blind, randomized trial (Study 1) was conducted in newly diagnosed patients with multi-drug resistant pulmonary Mycobacterium tuberculosis. Patients were randomized to receive treatment with:. Bedaquiline) and other drugs used to treat MDR-TB (SIRTURO. Treatment group) (n=79); or. Placebo plus other drugs used to treat MDR-TB (placebo treatment group) (n=81). Cycloserine/terizidone or available alternative. Time to ...
sirturo.com
SIRTURO® (bedaquiline)| Mechanism of Action| Official Website
http://www.sirturo.com/about-sirturo
FOR HEALTHCARE PROFESSIONALS IN THE US AND PUERTO RICO ONLY. Use in Specific Populations. Bedaquiline) Is a First-in-Class ATP Synthase Inhibitor for Pulmonary Multi-drug Resistant TB (MDR-TB). Adds a novel mechanism of action to the treatment of pulmonary MDR-TB. Is the first anti-TB drug to interfere with bacterial energy metabolism. It is mechanistically and structurally unrelated to current first-line agents. Download a comprehensive resource on SIRTURO. By directly observed therapy (DOT). WARNINGS: ...
sirturo.com
SIRTURO® (bedaquiline) | Appropriate Use | Patient Access
http://www.sirturo.com/sirturo-appropriate-use
FOR HEALTHCARE PROFESSIONALS IN THE US AND PUERTO RICO ONLY. Bedaquiline) is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in the treatment of adults (≥18 years) with pulmonary multi drug resistant tuberculosis (MDR TB). Reserve SIRTURO. For use when an effective treatment regimen cannot otherwise be provided. Administer SIRTURO. By directly observed therapy (DOT). Do not use SIRTURO. For the treatment of:. Latent infection due to. The safety and efficacy of SIRTURO.
sirturo.com
References | SIRTURO® (bedaquiline)
http://www.sirturo.com/references
FOR HEALTHCARE PROFESSIONALS IN THE US AND PUERTO RICO ONLY. American Thoracic Society and Centers for Disease Control and Prevention. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. Am J Respir Crit Care Med. Andries K, Verhasselt P, Guillemont J. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. Lalloo UG, Ambaram A. New antituberculous drugs in development. Curr HIV/AIDS Rep. Tuberculosis fact sheet. World Health Organization&...
sirturo.com
Medical Information Questions | SIRTURO® (bedaquiline)
http://www.sirturo.com/medical-information-center
FOR HEALTHCARE PROFESSIONALS IN THE US AND PUERTO RICO ONLY. Thank you for your interest in contacting Janssen Medical Information. Please note that we can only provide information about products marketed within the United States and must refer international inquiries to our affiliates. For additional information, please visit our website at www.JanssenMD.com/. Janssen Medical Information can be reached by phone at 1-800-JANSSEN. Healthcare professionals can submit questions using the contact us. In the ...
sirturo.com
Learn about SIRTURO| SIRTURO® (bedaquiline)
http://www.sirturo.com/multidrug-resistant-tb
FOR HEALTHCARE PROFESSIONALS IN THE US AND PUERTO RICO ONLY. The Critical Challenge of Drug Resistance. Anyone can be infected with tuberculosis (TB), but the overall proportion of infected individuals who progress to active disease is approximately 10%. Although efficacious anti-TB drugs have been available for decades, drug resistance in Mycobacterium tuberculosis. Has also been a challenge. TB bacteria can acquire resistance to antibiotics during drug treatment if a patient with TB:. Strains of TB res...
sirturo.com
Important Safety Information | Warnings | SIRTURO® (bedaquiline)
http://www.sirturo.com/important-safety-information
FOR HEALTHCARE PROFESSIONALS IN THE US AND PUERTO RICO ONLY. Use in Specific Populations. WARNINGS: INCREASED MORTALITY; QT PROLONGATION. An increased risk of death was seen in the SIRTURO. Treatment group (9/79, 11.4%) compared to the placebo treatment group (2/81, 2.5%) in one placebo-controlled trial. Only use SIRTURO. When an effective treatment regimen cannot otherwise be provided. QT prolongation can occur with SIRTURO. An increased risk of death was seen in the SIRTURO. The following may increase ...
